Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Dr. Stephen Robinson of the Bristol Hematology Oncology Centre discusses the treatment methods involved in mantle cell lymphoma (MCL). MCL is a type of non-Hodgkin lymphoma with a relatively poor prognosis. The first-line treatment in response to MCL is an autologous transplant, other treatments include allogeneic transplantation however, there is no definitive treatment plan. A large retrospective study with EBMT was carried out to investigate the efficacy of allogeneic transplantation in MCL and results suggest that it should not be used as a first-line treatment due to evidence of association with significant toxicity. Recorded at the 2017 annual meeting of the European Society for Blood and Marrow Transplantation
We use necessary cookies to make this site work. Analytics, preference, and marketing cookies are used only if you choose to allow them. You can change your choice at any time. For more information view our Cookie Policy.